Next Article in Journal
A Multi-Omics Protocol for Swine Feces to Elucidate Longitudinal Dynamics in Microbiome Structure and Function
Next Article in Special Issue
Eosinopenia in COVID-19 Patients: A Retrospective Analysis
Previous Article in Journal
Unravelling the Features of Success of VIM-Producing ST111 and ST235 Pseudomonas aeruginosa in a Greek Hospital
Previous Article in Special Issue
Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses
microorganisms-logo
Article Menu

Article Menu

Open AccessArticle

Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study

1
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
2
Hematology Laboratory Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
3
Public Health Laboratories, Hellenic Pasteur Institute, 11521 Athens, Greece
4
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
5
Institute of Chemical Biology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 11635 Athens, Greece
6
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
7
Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
8
BMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, Greece
9
Department of Transfusion Service and Clinical Hemostasis, “Saint Savvas” Oncology Hospital, 11522 Athens, Greece
10
Blood Bank, Evangelismos General Hospital, 10442 Athens, Greece
11
Department of Internal Medicine, Sotiria General Hospital of Chest Diseases, 11527 Athens, Greece
12
BMT Unit, University Hospital of Patras, School of Medicine, University of Patras, 26500 Patras, Greece
13
Fourth Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
14
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
15
Oncology Unit, Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
16
Hellenic National Blood Transfusion Center, 13678 Athens, Greece
17
Pharmacology Laboratory, School of Medicine, University of Patras, 26500 Patras, Greece
18
National Public Health Organization, 15123 Athens, Greece
19
Biomedical Systems Laboratory, National Technical University of Athens, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
Equal contribution as first authors.
Equal contribution as last authors.
Microorganisms 2020, 8(12), 1885; https://doi.org/10.3390/microorganisms8121885
Received: 29 October 2020 / Revised: 20 November 2020 / Accepted: 27 November 2020 / Published: 28 November 2020
(This article belongs to the Special Issue COVID-19: Focusing on Epidemiologic, Virologic, and Clinical Studies)
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14–104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers. View Full-Text
Keywords: Covid-19; SARS-CoV-2; novel coronavirus; convalescent plasma; antibodies Covid-19; SARS-CoV-2; novel coronavirus; convalescent plasma; antibodies
Show Figures

Figure 1

MDPI and ACS Style

Terpos, E.; Politou, M.; Sergentanis, T.N.; Mentis, A.; Rosati, M.; Stellas, D.; Bear, J.; Hu, X.; Felber, B.K.; Pappa, V.; Pagoni, M.; Grouzi, E.; Labropoulou, S.; Charitaki, I.; Ntanasis-Stathopoulos, I.; Moschandreou, D.; Bouhla, A.; Saridakis, S.; Korompoki, E.; Giatra, C.; Bagratuni, T.; Pefanis, A.; Papageorgiou, S.; Spyridonidis, A.; Antoniadou, A.; Kotanidou, A.; Syrigos, K.; Stamoulis, K.; Panayiotakopoulos, G.; Tsiodras, S.; Alexopoulos, L.; Dimopoulos, M.A.; Pavlakis, G.N. Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms 2020, 8, 1885.

AMA Style

Terpos E, Politou M, Sergentanis TN, Mentis A, Rosati M, Stellas D, Bear J, Hu X, Felber BK, Pappa V, Pagoni M, Grouzi E, Labropoulou S, Charitaki I, Ntanasis-Stathopoulos I, Moschandreou D, Bouhla A, Saridakis S, Korompoki E, Giatra C, Bagratuni T, Pefanis A, Papageorgiou S, Spyridonidis A, Antoniadou A, Kotanidou A, Syrigos K, Stamoulis K, Panayiotakopoulos G, Tsiodras S, Alexopoulos L, Dimopoulos MA, Pavlakis GN. Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms. 2020; 8(12):1885.

Chicago/Turabian Style

Terpos, Evangelos; Politou, Marianna; Sergentanis, Theodoros N.; Mentis, Andreas; Rosati, Margherita; Stellas, Dimitris; Bear, Jenifer; Hu, Xintao; Felber, Barbara K.; Pappa, Vassiliki; Pagoni, Maria; Grouzi, Elisavet; Labropoulou, Stavroula; Charitaki, Ioanna; Ntanasis-Stathopoulos, Ioannis; Moschandreou, Dimitra; Bouhla, Anthi; Saridakis, Stylianos; Korompoki, Eleni; Giatra, Chara; Bagratuni, Tina; Pefanis, Angelos; Papageorgiou, Sotirios; Spyridonidis, Alexandros; Antoniadou, Anastasia; Kotanidou, Anastasia; Syrigos, Konstantinos; Stamoulis, Konstantinos; Panayiotakopoulos, George; Tsiodras, Sotirios; Alexopoulos, Leonidas; Dimopoulos, Meletios A.; Pavlakis, George N. 2020. "Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study" Microorganisms 8, no. 12: 1885.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop